Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza A viruses with polymerase acidic subunit substitutions.

Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza A viruses with polymerase acidic subunit substitutions. Antiviral Res. 2020 Sep 25;:104951 Authors: Saito R, Osada H, Wagatsuma K, Chon I, Sato I, Kawashima T, Saito T, Kodo N, Ono Y, Shimada Y, Phyu W, Shobugawa Y Abstract We conducted a prospective, multicenter, non-randomized observational study to assess the duration of fever and symptoms of influenza A/H1N1pdm09 and A/H3N2 infected children < 19 years old treated with either baloxavir or oseltamivir. Additionally, these symptoms were investigated in association with pre- and post-baloxavir treatment-emergent polymerase acidic unit (PA) variants as compared to non-substituted viruses. Following receipt of informed consent, baloxavir was administered to 102 influenza A patients, and oseltamivir to 52 patients during the 2018-2019 influenza season in Japan. The average age was higher in the baloxavir treatment group compared to the oseltamivir treatment group (10.6 ± 2.7 versus 6.9 ± 2.9 years old, p<0.01). The duration of fever and symptoms in baloxavir-treated A/H1N1pdm09 and A/H3N2-infected children did not differ from those in oseltamivir-treated groups (median 22.0, 11.8, 23.0, and 21.0 hours, and median 114.5, 121.0, 123.0, and 122.0 hours, respectively). One (1.2%) of 83 A/H3N2 patients possessed a PA/I38T s...
Source: Antiviral Research - Category: Virology Authors: Tags: Antiviral Res Source Type: research